Skip to content
Annika Bansal – Lifestyle
Author:
Servier Pharmaceuticals
Servier Presents Long-Term INDIGO Analyses Demonstrating Sustained Clinical Benefit of VORANIGO® (vorasidenib) in IDH-Mutant Glioma Across Subgroups at SNO 2026
November 18, 2026
Servier Presents Updated Four-Year Results from Phase 2 FIREFLY-1 Study of OJEMDA® (tovorafenib) in Pediatric Low-Grade Glioma (pLGG) at SNO 2026
November 16, 2026
Servier Highlights Growing Neuro-Oncology Portfolio with New Data Across Pediatric and Adult Glioma at SNO 2026
November 9, 2026
Servier Announces First Patients Dosed in Pivotal Phase 2 EMBLEM-1 Cohort Evaluating Emiltatug Ledadotin (Emi-Le) in Adenoid Cystic Carcinoma
October 19, 2026
Axonius Introduces Information Assurance Vulnerability Management for Axonius Asset Cloud to Close Asset Intelligence Gap for U.S. Defense Agencies
August 29, 2026
Servier Presentations at ISPNO 2026 Highlight Neuro-Oncology Leadership and Expanding Glioma Portfolio
June 26, 2026
Servier Announces First Patient Enrolled in Phase Ib/II Study for the Treatment of a Rare Pediatric Epilepsy Syndrome in the U.S.
June 25, 2026
Promising Phase 1 Data for Servier’s Emiltatug Ledadotin (Emi-Le) in Adenoid Cystic Carcinoma (ACC) Presented at ASCO 2026
June 1, 2026
Servier to Present Extended Follow-Up Results from the Phase 3 INDIGO Trial Showing Durable and Sustained Treatment Benefits of VORANIGO® (vorasidenib) at ASCO 2026
June 1, 2026